A Randomised Phase II/III Trial of Weekly Cisplatin Chemoradiotherapy +/- low-dose celecoxib for locoregional nasopharyngeal carcinoma

Phase 2

Completed

• Conditions: asopharyngeal cancer; Nasopharyngeal cancer; Cancer - Head and neck

• Registration Number: ACTRN12608000449336
• Lead Sponsor: Shiraz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2008-09-12
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

1. Pathologically proven locoregional nasopharyngeal carcinoma.
2. No prior therapy
3. No clinical or imaging evidence of distant metastasis at the time of study enrollment
4. Karnofsky performance status = 70
5. Written informed consent
6. Normal or acceptable liver, kidney and bone marrow function

Exclusion Criteria

1. Prior therapy
2. Clinical or imaging evidence of distant metastasis
3. Patients with a known contraindication (e.g. gastric ulcer) or allergy to COX-2 inhibitors
4. Patients with severe heart, cardiovascular, liver, renal, inflammatory intestinal or blood coagulation disorders,

Study & Design

• Study Type: Interventional
• Study Design: Not specified